Polygenic Score (PGS) ID: PGS000663

Predicted Trait
Reported Trait Pancreatic cancer
Mapped Trait(s) pancreatic carcinoma (EFO_0002618)
Released in PGS Catalog: Jan. 7, 2021
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name wGRS22
Development Method
Name Genome-wide significant variants
Parameters p<5e-8
Variants
Original Genome Build GRCh37
Number of Variants 22
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000123
Citation (link to publication) Kim J et al. Cancer Epidemiol Biomarkers Prev (2020)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 86.6%
Not Reported: 12.3%
Multi-ancestry (excluding European): 1.1%
  • Hispanic or Latin American
  • African
  • Additional Asian Ancestries
  • Not Reported
57,275 individuals (100%)
PGS Evaluation
European: 100%
2 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST002991
Europe PMC: 26098869
 636 individuals Hispanic or Latin American, African unspecified, Asian unspecified, NR 9 cohorts
  • IARC
  • ,JHH
  • ,MAYO
  • ,MDACCS
  • ,MSKCC
  • ,QIMR
  • ,Toronto
  • ,UCSF
  • ,Yale
GWAS Catalog: GCST002553
Europe PMC: 25086665
 6,785 individuals European 16 cohorts
  • AHS
  • ,ATBC
  • ,CPSII
  • ,DFCI-GCC
  • ,EPIC
  • ,HPFS
  • ,MCCS
  • ,MEC
  • ,NHS
  • ,PANDoRA
  • ,PANKRAS-II
  • ,PHS
  • ,PLCO
  • ,SELECT
  • ,VITAL
  • ,WHI
GWAS Catalog: GCST002991
Europe PMC: 26098869
 7,046 individuals NR 9 cohorts
  • IARC
  • ,JHH
  • ,MAYO
  • ,MDACCS
  • ,MSKCC
  • ,QIMR
  • ,Toronto
  • ,UCSF
  • ,Yale
GWAS Catalog: GCST002991
Europe PMC: 26098869
 7,320 individuals European 9 cohorts
  • IARC
  • ,JHH
  • ,MAYO
  • ,MDACCS
  • ,MSKCC
  • ,QIMR
  • ,Toronto
  • ,UCSF
  • ,Yale
GWAS Catalog: GCST005434
Europe PMC: 29422604
 21,536 individuals European 28 cohorts
  • AHS
  • ,ATBC
  • ,CLUEII
  • ,CPSII
  • ,DFCI-GCC
  • ,EPIC
  • ,HPFS
  • ,IARC
  • ,JHH
  • ,MAYO
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MSKCC
  • ,NHS
  • ,NYU-WHS
  • ,PANDoRA
  • ,PANKRAS-II
  • ,PHS
  • ,PLCO
  • ,QIMR
  • ,SELECT
  • ,SMWHS
  • ,UCSF
  • ,VITAL
  • ,WHI
  • ,WHS
  • ,Yale
GWAS Catalog: GCST003758
Europe PMC: 27579533
 13,952 individuals European 28 cohorts
  • AHS
  • ,ATBC
  • ,CLUEII
  • ,CPSII
  • ,DFCI-GCC
  • ,EPIC
  • ,HPFS
  • ,Iowa-Mayo
  • ,JHH
  • ,MCCS
  • ,MDACCS
  • ,MEC
  • ,MSKCC
  • ,NHS
  • ,NYU-WHS
  • ,PACIFIC
  • ,PANDoRA
  • ,PANKRAS-II
  • ,PHS
  • ,PLCO
  • ,SELECT
  • ,SMWHS
  • ,Toronto
  • ,UCSF
  • ,VITAL
  • ,WHI
  • ,WHS
  • ,Yale

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM001367 PSS000598|
European Ancestry|
1,591 individuals
 PGP000123 |
Kim J et al. Cancer Epidemiol Biomarkers Prev (2020)
 Reported Trait: Pancreatic cancer OR: 1.37 [1.23, 1.53] — — — Cross validation approach-testing sample = 20%
PPM001368 PSS000597|
European Ancestry|
956 individuals
 PGP000123 |
Kim J et al. Cancer Epidemiol Biomarkers Prev (2020)
 Reported Trait: Pancreatic cancer (0-10 years of follow-up) OR: 1.46 [1.27, 1.68] — — — Cross validation approach-testing sample = 20%
PPM001369 PSS000598|
European Ancestry|
1,591 individuals
 PGP000123 |
Kim J et al. Cancer Epidemiol Biomarkers Prev (2020)
 Reported Trait: Pancreatic cancer OR: 1.37 [1.22, 1.53] AUROC: 0.65 — matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, month/year of blood collection, body mass index, waist-to-hip ratio, diabetic status Cross validation approach-testing sample = 20%
PPM001370 PSS000597|
European Ancestry|
956 individuals
 PGP000123 |
Kim J et al. Cancer Epidemiol Biomarkers Prev (2020)
 Reported Trait: Pancreatic cancer (0-10 years of follow-up) OR: 1.44 [1.25, 1.67] AUROC: 0.67 — matching factors, age, cohort (also gender), race/ethnicity, smoking status, fasting status, month/year of blood collection, body mass index, waist-to-hip ratio, diabetic status Cross validation approach-testing sample = 20%

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000597 In this study, cases were incident patients with primary pancreatic adenocarcinoma ascertained between 1984 and 2010 through self- report, report of next-of-kin, or death certificates and confirmed by medical record review and tumor registry data. Cases Diagnosed within 10 years of blood collection. Mean = 10.0 years
[
  • 304 cases
  • , 652 controls
]
,
28.1 % Male samples
 — European — HPFS, NHS, PHS, WHI Overlap with GWAS samples (percentage unknown). Cross validation approach used (20% as testing sample)
PSS000598 In this study, cases were incident patients with primary pancreatic adenocarcinoma ascertained between 1984 and 2010 through self- report, report of next-of-kin, or death certificates and confirmed by medical record review and tumor registry data. —
[
  • 500 cases
  • , 1,091 controls
]
,
33.4 % Male samples
 — European — HPFS, NHS, PHS, WHI Overlap with GWAS samples (percentage unknown). Cross validation approach used (20% as testing sample)